Rhopressa®
netarsudil 0.02% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension
1 drop in the affected eye(s) once daily in the evening
Lowers IOP 3.9 to 4.7 mm Hg from baseline, sustained over 6 months.
OFF-LABELNot in the FDA label for this product
Corneal edema from Fuchs endothelial corneal dystrophy
0.02%, 1 drop once daily for 8 weeks; twice daily was also studied, with no significant difference between the two regimens at any time point
Phase 2 open-label · n=40
Phase 2 randomized open-label parallel-group trial, 40 patients with central corneal thickness 600 micrometers or more: mean central corneal thickness fell 28.4 micrometers at week 4 on once-daily dosing (P=0.0021) and 20.1 micrometers on twice-daily (P=0.0335), 12.5% of patients had complete resolution of corneal edema, and 25% gained 10 or more letters at week 4 (5 patients in each arm). Reticular edema developed in one patient on twice-daily dosing and resolved on discontinuation; this indication is not FDA approved.
Contraindications
None listed on the FDA label.
0.02% (0.2 mg/mL) ophthalmic solution, 2.5 mL fill in a 4 mL bottle
Rho kinase inhibitor believed to reduce IOP by increasing the outflow of aqueous humor through the trabecular meshwork. The exact mechanism is unknown. A double-masked, randomized, vehicle-controlled, phase 2 trial in 20 patients with primary open angle glaucoma or ocular hypertension found a treatment difference of 0.03 µL/min/mm Hg in mean diurnal outflow facility and -0.89 mm Hg in mean diurnal episcleral venous pressure change; the authors conclude netarsudil acts on the conventional outflow pathway, both proximal and distal.
Warnings & Precautions
- Epithelial corneal edema: Honeycomb or bullous edema has been reported in some patients with pre-existing corneal stromal edema or after ocular procedures that could affect corneal endothelial function; it typically resolves after discontinuation. Advise patients to notify their physician if they experience eye pain or decreased vision.
- Bacterial keratitis: Reported with contaminated multiple-dose containers, in most cases in eyes with concurrent corneal disease or a disrupted epithelial surface.
- Use with contact lenses: Benzalkonium chloride 0.015% may be absorbed by soft lenses; remove before instillation and reinsert after 15 minutes.
Common Side Effects
Conjunctival hyperemia is the most common ocular adverse reaction, reported in 53% of patients, and 6% of patients discontinued therapy for it. Corneal verticillata, instillation site pain, and conjunctival hemorrhage each occurred in approximately 20%, and instillation site erythema, corneal staining, blurred vision, increased lacrimation, eyelid erythema, and reduced visual acuity in 5% to 10%. Corneal verticillata were first noted at 4 weeks of daily dosing, did not result in any apparent visual functional changes, and most resolved after discontinuation. In postmarketing use, epithelial corneal edema has been reported in some patients with pre-existing corneal stromal edema or after ocular procedures that could affect corneal endothelial function.
Pregnancy: No human data, and systemic exposure after ocular dosing is low; IV dosing of pregnant rats and rabbits through organogenesis produced no adverse embryofetal effects at clinically relevant systemic exposures. In rats, abortion and embryofetal lethality occurred at 126 times the plasma exposure at the recommended human ophthalmic dose by Cmax (NOAEL 40 times), and in rabbits, embryofetal lethality at 1480 times and malformations at 1330 times and above (NOAEL 214 times).
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production; systemic exposure after ocular dosing is low.
Safety and effectiveness below age 18 not established.